Lupin shares Phase 1 data on LNP8701 at ASCO 2026
Lupin Limited shared Phase 1a trial results for LNP8701 at the ASCO 2026 Annual Meeting, indicating the SOS1 inhibitor was well tolerated with favorable anti-tumor activity. The study reported stable disease in patients undergoing monotherapy, with plans to continue efficacy studies in a phase 1b trial in India.
*this image is generated using AI for illustrative purposes only.
Lupin Limited announced that results from its Phase 1a trial evaluating LNP8701 have been accepted for publication at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting, held from May 29-June 2, 2026, in Chicago, IL. The abstract reports findings from an ongoing first-in-human study of LNP8701, an orally administered SOS1 inhibitor designed to block SOS1-mediated RAS activation. Results indicate that LNP8701 was well tolerated with a desirable safety profile and favorable anti-tumor activity.
The preliminary efficacy findings demonstrate that two patients completed LNP8701 monotherapy for 12 cycles and one patient completed 14 cycles with stable disease. Vinita Gupta, CEO, Lupin, said the findings highlight the emerging potential of LNP8701 and signal progress in the pursuit of novel therapies for difficult-to-treat cancers.
Current data suggest that LNP8701 is safe and well-tolerated across all tested dosing levels. Lupin will continue to study the efficacy of LNP8701 in its phase 1b trial in India and explore its potential to treat solid tumors both as a monotherapy and as part of a combination.
Abstract Details
| Detail | Information |
|---|---|
| Abstract Number | e15162 |
| Track | Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology |
| Citation | J Clin Oncol 44, 2026 (suppl 16; abstr e15162) |
| DOI | 10.1200/JCO.2026.44.16_suppl.e15162 |
| Clinical Trial Registration Number | CTRI/2024/08/072373 |
| Abstract Link | https://www.asco.org/abstracts-presentations/264586 |
Historical Stock Returns for Lupin
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.38% | -0.78% | -2.44% | +9.48% | +15.10% | +88.45% |
What specific combination therapies does Lupin plan to prioritize in the Phase 1b trial for treating solid tumors?
How will the safety and efficacy data from the upcoming Phase 1b trial in India influence the design of potential global studies?
What is the projected timeline for initiating Phase 2 trials based on the current progress of LNP8701?
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
